Senzime AB Financials
| SEZI Stock | SEK 5.80 0.13 2.29% |
Senzime |
Please note, the imprecision that can be found in Senzime AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Senzime AB. Check Senzime AB's Beneish M Score to see the likelihood of Senzime AB's management manipulating its earnings.
Senzime AB Stock Summary
Senzime AB competes with BioInvent International, Orexo AB, Alligator Bioscience, Swedish Orphan, and Anoto Group. Senzime AB develops patient-oriented monitoring systems that assess patients biochemical and physiological processes before, during and after surgery in Sweden. Senzime AB was founded in 1997 and is based in Uppsala, Sweden. Senzime AB is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0002478776 |
| Business Address | Ulls vAeg 41, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | senzime.com |
| Phone | 46 18 51 56 40 |
| Currency | SEK - Swedish Kronor |
You should never invest in Senzime AB without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Senzime Stock, because this is throwing your money away. Analyzing the key information contained in Senzime AB's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Senzime AB Key Financial Ratios
Senzime AB's financial ratios allow both analysts and investors to convert raw data from Senzime AB's financial statements into concise, actionable information that can be used to evaluate the performance of Senzime AB over time and compare it to other companies across industries.Senzime Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Senzime AB's current stock value. Our valuation model uses many indicators to compare Senzime AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Senzime AB competition to find correlations between indicators driving Senzime AB's intrinsic value. More Info.Senzime AB is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Senzime AB's earnings, one of the primary drivers of an investment's value.Senzime AB Systematic Risk
Senzime AB's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Senzime AB volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Senzime AB correlated with the market. If Beta is less than 0 Senzime AB generally moves in the opposite direction as compared to the market. If Senzime AB Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Senzime AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Senzime AB is generally in the same direction as the market. If Beta > 1 Senzime AB moves generally in the same direction as, but more than the movement of the benchmark.
Senzime AB December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Senzime AB help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Senzime AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Senzime AB based on widely used predictive technical indicators. In general, we focus on analyzing Senzime Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Senzime AB's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 14.51 | |||
| Value At Risk | (3.43) | |||
| Potential Upside | 4.66 |
Additional Tools for Senzime Stock Analysis
When running Senzime AB's price analysis, check to measure Senzime AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senzime AB is operating at the current time. Most of Senzime AB's value examination focuses on studying past and present price action to predict the probability of Senzime AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senzime AB's price. Additionally, you may evaluate how the addition of Senzime AB to your portfolios can decrease your overall portfolio volatility.